NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMS · Real-Time Price · USD
17.63
+0.32 (1.85%)
May 29, 2025, 4:00 PM - Market closed
1.85%
Market Cap 1.98B
Revenue (ttm) 47.14M
Net Income (ttm) -187.36M
Shares Out 112.27M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 359,498
Open 17.33
Previous Close 17.31
Day's Range 17.29 - 17.70
52-Week Range 14.06 - 27.29
Beta 0.01
Analysts Strong Buy
Price Target 42.83 (+142.94%)
Earnings Date May 8, 2025

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMS
Full Company Profile

Financial Performance

In 2024, NAMS's revenue was $45.56 million, an increase of 223.37% compared to the previous year's $14.09 million. Losses were -$241.60 million, 36.5% more than in 2023.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price forecast is $42.83, which is an increase of 142.94% from the latest price.

Price Target
$42.83
(142.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...

2 days ago - GlobeNewsWire

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...

15 days ago - GlobeNewsWire

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Jour...

21 days ago - GlobeNewsWire

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) –

22 days ago - GlobeNewsWire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...

27 days ago - GlobeNewsWire

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers Presentations include new data from BROADWAY...

4 weeks ago - GlobeNewsWire

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...

2 months ago - GlobeNewsWire

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to fi...

3 months ago - Seeking Alpha

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures...

3 months ago - Seeking Alpha

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 --

3 months ago - GlobeNewsWire

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

3 months ago - GlobeNewsWire

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...

5 months ago - GlobeNewsWire

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...

6 months ago - GlobeNewsWire

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

NewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data en...

6 months ago - Seeking Alpha

Top 3 Health Care Stocks That May Collapse This Quarter

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: ADPTFNA
6 months ago - Benzinga

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...

6 months ago - GlobeNewsWire

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

On Tuesday, NewAmsterdam Pharma Company N.V.  NAMS revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (...

6 months ago - Benzinga

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p

6 months ago - GlobeNewsWire

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P ...

6 months ago - GlobeNewsWire

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

7 months ago - GlobeNewsWire

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory...

8 months ago - Seeking Alpha

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

9 months ago - GlobeNewsWire

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Needham has initiated coverage on NewAmsterdam Pharma Company N.V NAMS, a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.

9 months ago - Benzinga

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

10 months ago - GlobeNewsWire

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

-- Company expects to report topline data in the first quarter of 2025 -- -- Company expects to report topline data in the first quarter of 2025 --

11 months ago - GlobeNewsWire